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Abstract 18 
Background: 19 
Cancer stem cells (CSCs) have innate abilities to resist even the harshest of therapies. To 20 
eradicate CSCs, parallels can be drawn from signalling modules that orchestrate pluripotency. 21 
Notch-Hedgehog hyperactivation are seen in CSCs, yet, not much is known about their 22 
conserved roles in tumour progression across cancers.  23 
Methods: 24 
Employing a comparative approach involving 21 cancers, we uncovered clinically-relevant, 25 
pan-cancer drivers of Notch and Hedgehog. GISTIC datasets were used to evaluate copy 26 
number alterations. Receiver operating characteristic and Cox regression were employed for 27 
survival analyses.  28 
Results: 29 
We identified a Notch-Hedgehog signature of 13 genes exhibiting high frequencies of somatic 30 
amplifications leading to transcript overexpression. The signature successfully predicted 31 
patients at risk of death in five cancers(n=2,278): glioma(P<0.0001), clear cell renal 32 
cell(P=0.0022), papillary renal cell(P=0.00099), liver(P=0.014) and stomach(P=0.011). The 33 
signature was independent of other clinicopathological parameters and offered additional 34 
resolution to stratify similarly-staged tumours. High-risk patients exhibited features of 35 
stemness and had more hypoxic tumours, suggesting that hypoxia may influence CSC 36 
behaviour. Notch-Hedgehog+ CSCs had an immune privileged phenotype associated with 37 
increased regulatory T cell function.  38 
Conclusion: This study will set the stage for exploring adjuvant therapy targeting the Notch-39 
Hedgehog axis to help optimise therapeutic regimes leading to successful CSC elimination.40 
Background: 41 
Tumours are far from homogeneous masses, yet many contemporary therapies continue to 42 
treat them as such. It has become increasingly clear that a minor population of tumour cells 43 
known as cancer stem cells (CSCs) contribute to treatment resistance as they have the 44 
propensity to tolerate DNA damage(1,2) and evade immune detection(3) to give rise to new 45 
tumours post therapy. Identification of CSCs has remained a challenging endeavour since 46 
they only make up a small proportion of the tumour and are histologically similar to non-47 
stem cancer cells. Moreover, molecular markers that identify CSCs are often cancer-type 48 
dependent, which limit their broad scale applications(4). CSCs share many qualities with 49 
embryonic or adult stem cells. For example, activation of signalling pathways involved in 50 
coordinating cellular homeostasis, morphogenesis and cell fate determination (TGF-β, Wnt, 51 
Notch and Hedgehog) are often seen in CSCs. These pathways rarely act in isolation and 52 
significant crosstalk between them have been reported(5). 53 
 54 
In order to fully exploit these pathways for CSC therapy, pan-cancer explorations are 55 
warranted to reveal conserved components that can be prioritised as therapeutic targets. 56 
Concentrating on Notch and Hedgehog signalling pathways, we seek to attain a 57 
comprehensive understanding of how somatic copy number alterations and expression 58 
profiles of pathway genes along with their downstream targets could influence tumour 59 
progression and prognosis. The role of Notch signalling in oncogenesis was initially 60 
discovered in T cell acute lymphoblastic leukaemia(6). Since then, multiple studies on Notch 61 
signalling have demonstrated both oncogenic and tumour suppressive functions in 62 
haematological and solid malignancies, implying its pleiotropic nature that is very much 63 
dependent on cellular types(7). Hedgehog is a morphogen that regulates a signalling cascade 64 
involving the Smoothened protein to influence morphogenetic processes such as 65 
proliferation and differentiation(8). Interactions between Notch and Hedgehog signalling 66 
have been demonstrated in multiple cancers. Hes1, a Notch effector, is targeted by sonic 67 
hedgehog in neural cells(9). When Patched, a negative regulator of Hedgehog, is abrogated in 68 
mice, this gives rise to medulloblastoma with enhanced Notch signalling(10). Hedgehog 69 
signalling promotes the expression of Jagged2 (a Notch ligand)(11) and in ovarian cancer 70 
mice models, inhibition of Jagged1 would sensitise tumours to docetaxel treatment by 71 
affecting GLI2 function(12). Concurrent activation of Hedgehog and Notch signalling was 72 
observed in prostate cancer cells that were resistant to docetaxel(13). Glioblastoma treated 73 
with a Notch inhibitor was subsequently desensitised to further Notch suppression as they 74 
upregulate Hedgehog signalling(14).  75 
 76 
These studies highlight the importance of Notch-Hedgehog interactions in cancer, which calls 77 
for a better understanding of their relationship and also to reveal crosstalk with other 78 
pathways involved in regulating CSC function. Harnessing genomic and transcriptomic 79 
sequences of 21 cancer types, we performed a comprehensive investigation linking genomic 80 
alterations to transcriptional dysregulation of Notch-Hedgehog pathway genes. We 81 
discovered conserved patterns of Notch-Hedgehog hyperactivation across cancers and 82 
revealed putative driver genes that were associated with CSC phenotypes underpinning poor 83 
clinical outcomes. We also examined the relationship between the tumour 84 
microenvironment (hypoxia and immune suppression) and Notch-Hedgehog+ CSCs. In-depth 85 
knowledge of the Notch-Hedgehog signalling axis afforded by this study will set the stage for 86 
exploring combinatorial chemotherapy targeting both pathways simultaneously to potentially 87 
eradicate CSCs.    88 
Materials and Methods: 89 
A total of 72 genes associated with Notch and Hedgehog signalling were retrieved from the 90 
Kyoto Encyclopedia of Genes and Genomes (KEGG) database listed in Table S1. 91 
 92 
Study cohorts 93 
We retrieved transcriptomic and genomic profiles of 21 cancer types (n=18,484) including 94 
their non-tumour counterparts from The Cancer Genome Atlas and Broad Institute GDAC 95 
Firehose(15) (Table S2).  96 
 97 
Somatic copy number alterations analyses 98 
We retrieved Firehose Level 4 copy number variation datasets in the form of GISTIC gene-99 
level tables, which provided discrete amplification and deletion indicators(16). A sample was 100 
defined as ‘deep amplification’ for values that were higher than the maximum median copy-101 
ratio for each chromosome arm (+2). Samples with values less than the minimum median 102 
copy-ratio for each chromosome arm were called ‘deep deletions’ (-2). GISTIC indicators of 103 
+1 and -1 represented shallow amplifications and deletions respectively.  104 
 105 
Calculating Notch-Hedgehog 13-gene scores, hypoxia scores and regulatory T cell (Treg) scores 106 
The Notch-Hedgehog 13-gene signature was employed to calculate a score for each patient. 107 
It comprised of the following genes: JAG1, LFNG, DTX2, DLL3, GPR161, PSENEN, GLI1, HES1, 108 
PTCRA, DTX3L, ADAM17, KIF7 and NOTCH1. Hypoxia scores were calculated from 52 hypoxia 109 
signature genes(17). Treg scores were calculated based on the overlap between four Treg 110 
signatures(18–21), consisting of 31 genes: FOXP3, TNFRSF18, TNFRSF9, TIGIT, IKZF2, CTLA4, 111 
CCR8, TNFRSF4, IL2RA, BATF, IL2RB, CTSC, CD27, PTTG1, ICOS, CD7, TFRC, ERI1, GLRX, NCF4, 112 
PARK7, HTATIP2, FCRL3, CALM3, DPYSL2, CSF2RB, CSF1, IL1R2, VDR, ACP5 and MAGEH1. 113 
Scores were calculated from the average log2 expression values of 13, 52 or 31 genes 114 
representing Notch-Hedgehog, hypoxia and Tregs respectively. Kaplan-Meier analyses of the 115 
Notch-Hedgehog signature were performed on patients separated into quartiles based on 116 
their 13-gene scores. For analyses in Figures 4, 5 and 6, patients were separated into four 117 
groups using median 13-gene scores and median CSC transcription factor expression levels 118 
(EZH2, REST and SUZ12), hypoxia scores or Treg scores as thresholds for Kaplan-Meier and 119 
Cox regression analyses. Nonparametric Spearman’s rank-order correlation tests were used 120 
to investigate the relationship between 13-gene scores and TF expression levels, hypoxia 121 
scores or Treg scores.  122 
 123 
Multidimensional scaling, differential expression and survival analyses 124 
As per the journal’s guidelines, we have not repeated methods here as we have previously 125 
published detail methods for multidimensional scaling (MDS), differential expression and 126 
survival analyses(22–24). Briefly, MDS analysis was employed to visualise samples’ distance 127 
(tumour and non-tumour) in reduced 2-dimensional space. The R vegan package was 128 
employed for MDS ordination using Euclidean distances. Permutational multivariate analysis 129 
of variance (PERMANOVA) was used to investigate statistical differences between tumour 130 
and non-tumour samples. The linear model and Bayes method was employed for differential 131 
expression analyses, followed by the Benjamini-Hochberg false discovery rate method. 132 
Kaplan-Meier, Cox proportional hazards and receiver operating characteristic survival 133 
analyses were performed using R survminer, survival and survcomp packages.  134 
 135 
Functional enrichment and transcription factor (TF) analyses 136 
Differential expression analyses as mentioned previously were performed on patients 137 
separated into quartiles 4 and 1 based on their 13-gene scores. Differentially expressed 138 
genes were mapped against KEGG and Gene Ontology (GO) databases using GeneCodis(25) 139 
to determine pathways that were enriched. The Enrichr tool was used to determine whether 140 
differentially expressed genes were enriched for stem cell TFs binding targets by comparing 141 
chromatin immunoprecipitation sequencing profiles from ChEA and ENCODE databases(26).  142 
 143 
The R ggplot2 and pheatmap packages were used to generate all plots.    144 
Results: 145 
 146 
Recurrently amplified driver genes associated with Notch and Hedgehog activation in 21 147 
diverse cancer types 148 
 149 
To characterise the extent of Notch and Hedgehog signalling and identify common molecular 150 
subtypes, we examined somatic copy number alterations (SCNAs) and differential expression 151 
(tumour versus non-tumour) patterns of 72 genes in 18,484 cases of clinically annotated 152 
stage I to IV samples representing 21 cancer types (Fig. 1A; Table S1; Table S2). We found 153 
that 70 out of 72 genes were recurrently amplified in at least 20% of samples per cancer type 154 
in at least one cancer type (Fig. 1A). Lung squamous cell carcinoma (LUSC) had the highest 155 
fraction of samples harbouring amplified Hedgehog genes, while endometrial cancer (UCEC) 156 
had the fewest somatic gains (Fig. 1B). When considering Notch gene amplifications, LUSC 157 
also emerged as the top candidate while clear cell renal cell carcinoma (KIRC) had the fewest 158 
number of Notch gene amplifications (Fig. 1B). In terms of focal deletions, this was also the 159 
highest in LUSC for Hedgehog genes and renal chromophobe carcinoma (KICH) for Notch 160 
genes (Fig. 1B).  161 
 162 
Focusing on recurrently amplified genes, we identified 35 genes (Hedgehog pathway: 13 163 
genes; Notch pathway: 22 genes) that were gained in >20% of samples and in at least one-164 
third of cancer types (> 7 cancers) (Fig. 1C). GLI3, SMURF1, RBPJL, JAG1, LFNG and DTX2 were 165 
some of the most amplified genes present in at least 18 cancers (Fig. 1C). In contrast, KIF7, 166 
NOTCH1, MAML and ADAM17 were the least amplified genes (Fig. 1C). LUSC had the highest 167 
number of amplified genes (34 genes) followed by 33 genes in oesophageal carcinoma (ESCA) 168 
and stomach and oesophageal carcinoma (STES) and 32 genes in stomach adenocarcinoma 169 
(STAD) and bladder urothelial carcinoma (BLCA) (Fig. 1C). In contrast, only 8 genes were 170 
amplified in UCEC (Fig. 1C). 171 
 172 
SCNA events associated with overexpression could represent candidate driver genes since 173 
positive correlations between gene amplification and overexpression are indicative of a gain-174 
of-function(27). Differential expression analyses between tumour and adjacent non-tumour 175 
samples revealed that 13 of the amplified genes were also significantly upregulated (> 1.5 176 
fold-change, P<0.05) in tumours of at least 7 cancer types (Fig. 1C). These genes were 177 
prioritised as a Notch-Hedgehog signature potentially representative of multiple cancers: 178 
JAG1, LFNG, DTX2, DLL3, GPR161, PSENEN, GLI1, HES1, PTCRA, DTX3L, ADAM17, KIF7 and 179 
NOTCH1 (Fig. 1C).  180 
 181 
 182 
A 13-gene Notch-Hedgehog signature predicts survival outcomes in five cancers 183 
 184 
Tumours displayed various degrees of somatic gains and overexpression of Notch-Hedgehog 185 
pathway genes (Fig. 1), suggesting that aberrant activation of these pathways may influence 186 
disease progression and survival outcomes. We employed univariate Cox proportional 187 
hazards regression analyses to test the prognostic roles of individual Notch-Hedgehog 188 
signature genes across 20 cancer types where survival data is available. Prognosis appeared 189 
to tissue type-dependent (Fig. S1). All 13 genes were prognostic in the glioma dataset 190 
(GBMLGG), consisting of samples from patients with astrocytoma, oligoastrocytoma, 191 
oligodendroglioma and glioblastoma multiforme (Fig. S1). A majority of the genes (9 out of 192 
13) were associated with poor prognosis (hazard ratio [HR] > 1, P<0.05) (Fig. S1). However, 193 
despite showing high frequencies of SCNAs (Fig. 1C), none of the 13 genes harboured 194 
prognostic information in patients with LUSC, cholangiocarcinoma (CHOL) or oesophageal 195 
carcinoma (ESCA) (Fig. S1).  196 
 197 
We next considered all 13 genes as a group in assessing prognosis. For each patient, we 198 
calculated their 13-gene scores by taking the average expression of all genes. Patients were 199 
separated into survival quartiles based on their 13-gene scores. Remarkably, Kaplan-Meier 200 
estimates and log-rank tests revealed that the 13-gene signature accurately predicted 201 
patients at higher risk of death in five cancer types (n=2,278): glioma (P<0.0001), clear cell 202 
renal cell (P=0.0022), papillary renal cell (P=0.00099), liver (P=0.014) and stomach (P=0.011) 203 
(Fig. 2A). Patients within the 4th quartile had significantly poorer survival rates compared to 204 
those within the 1st quartile: glioma (HR=3.386, P<0.0001), clear cell renal cell (HR=2.177, 205 
P=0.00048), papillary renal cell (HR=4.881, P=0.0053), liver (HR=2.627, P=0.0039) and 206 
stomach (HR=2.217, P=0.014) (Table S3). When comparing tumour and non-tumour 207 
expression patterns, Mann-Whitney-Wilcoxon tests revealed that a vast majority of the 13 208 
genes were significantly upregulated in tumours of these cancers (Fig. S2) where 209 
hyperactivation of Notch-Hedgehog signalling was associated with adverse survival outcomes 210 
(Fig. 2A). Multidimensional scaling analyses revealed that the 13 genes could accurately 211 
distinguish tumour from non-tumour samples in these cancers (Fig. 2B), suggesting that 212 
Notch-Hedgehog transcriptional states could be used to identify cells with oncogenic 213 
properties.   214 
 215 
Multivariate Cox proportional hazards regression was used to determine whether the 216 
signature was confounded by other clinicopathological features. Tumour, node, metastasis 217 
(TNM) staging is frequently used for patient stratification. Even after accounting for TNM 218 
staging, the signature remained an independent predictor of survival: clear cell renal cell 219 
(HR=1.731, P=0.014), papillary renal cell (HR=2.297, P=0.042), liver (HR=2.146; P=0.024) and 220 
stomach (HR=2.161, P=0.017) (Table S3). Given that both the signature and tumour stage 221 
were independent of each other, we reason that the signature could be used to improve 222 
TNM staging. We observed that Notch-Hedgehog driver genes offered an additional 223 
resolution in tumour classification for further stratification of similarly staged tumours in 224 
these cancers: clear cell renal cell (P<0.0001), papillary renal cell (P<0.0001), liver (P<0.0001) 225 
and stomach (P=0.0068) (Fig. 3A).   226 
 227 
Glioma samples are classified into four histological categories with varying severity: low-228 
grade astrocytoma, low-grade oligodendroglioma, low-grade oligoastrocytoma (consisting of 229 
both abnormal astrocytoma and oligodendroglioma cells), and grade IV glioblastoma 230 
multiforme. Kaplan-Meier analyses of glioma samples grouped by histology revealed that the 231 
signature remained prognostic in astrocytoma (P=0.038), oligoastrocytoma (P=0.0018) and 232 
glioblastoma multiforme (P=0.045) (Fig. 3B). Patients with low-grade gliomas stratified by the 233 
signature into the 4th quartile had significantly higher death risks compared to those within 234 
the 1st quartile: astrocytoma (HR=2.535, P=0.021), oligoastrocytoma (HR=4.169, P=0.014) 235 
and glioblastoma multiforme (HR=2.163, P=0.042) (Table S3).  236 
 237 
To evaluate the predictive performance of the signature, we employed receiver operating 238 
characteristic (ROC) analyses and compared area under the curves (AUCs) derived from the 239 
signature versus those derived from TNM staging. The signature had greater sensitivity and 240 
specificity in predicting 5-year overall survival compared to TNM staging: papillary renal cell 241 
(AUC=0.796 vs. AUC 0.640) and stomach (AUC=0.710 vs. AUC=0.561) (Fig. 3C). Importantly, 242 
when used as a combined model with TNM staging, it outperformed either the signature or 243 
TNM when considered alone, suggesting that incorporating molecular subtype information 244 
on Notch-Hedgehog signalling allowed more precise stratification: clear cell renal cell 245 
(AUC=0.802), papillary renal cell (AUC=0.812), liver (AUC=0.720) and stomach (AUC: 0.728) 246 
(Fig. 3C). In terms of predicting prognosis in glioma subtypes, performance of the signature 247 
was the best in oligoastrocytoma (AUC=0.823), followed by glioblastoma multiforme. 248 
(AUC=0.761) and astrocytoma (AUC=0.743) (Fig. 3C). The signature also performed well when 249 
all glioma subtypes were considered as a group (AUC=0.815) (Fig. 3C).  250 
 251 
 252 
The Notch-Hedgehog signature identifies molecular subtypes with stem cell-like features  253 
 254 
Notch-Hedgehog hyperactivation is associated with increased mortality rates (Fig. 2, 3). To 255 
further investigate the underlying biological consequences of augmented Notch-Hedgehog 256 
signalling and how they lead to adverse outcomes, we performed differential expression 257 
analyses on all transcripts comparing high- and low-risk patients as predicted by the 13-gene 258 
signature. The liver cancer cohort had the highest number of differentially expressed genes 259 
(DEGs): 3,015 genes (-1.5 > log2 fold change > 1.5; P<0.01) (Table S4). This was followed by 260 
glioma (1,407 genes), stomach (906 genes), papillary renal cell (817 genes) and clear cell 261 
renal cell (545 genes) carcinoma (Table S4). Despite having very different pathologies, there 262 
was a great deal of DEG overlap between these cancers. 14 DEGs were found in all five 263 
cancers, 164 DEGs were observed in at least four cancers and 470 DEGs in at least three 264 
cancers (Fig. S3A), implying conserved biological roles of Notch-Hedgehog signalling in driving 265 
disease progression.  266 
 267 
KEGG pathway analyses on DEGs demonstrated enrichments of pathways involved in 268 
regulating self-renewal and pluripotency, i.e. Wnt, TGF- β, MAPK, JAK-STAT and PPAR 269 
signalling (Fig. 3D; Fig. S3B), suggesting that tumours with hyperactive Notch-Hedgehog 270 
signalling were characterised by molecular footprints of stemness and that there was 271 
significant crosstalk between Notch-Hedgehog and other pathways involved in controlling 272 
tumour initiation(28,29). Additionally, Gene Ontology analyses revealed significant 273 
enrichments of processes related to cell differentiation, cell proliferation, embryo 274 
development and morphogenesis (Fig. 3D), supporting the hypothesis that tumour 275 
aggression and elevated mortality could be caused by the presence of cancer stem cells 276 
(CSCs) that are likely to be refractory to therapy. Consistent with these results, Enrichr 277 
transcription factor (TF) analyses revealed that TFs associated with stem cell function 278 
appeared amongst top enriched candidates (Fig. 3D). DEGs were enriched as binding targets 279 
of SUZ12, REST, EZH2, SMAD4 and FOXM1 as supported by both ChEA and ENCODE 280 
databases (Fig. 3D). Binding targets of SUZ12 and EZH2 were consistently enriched across all 281 
five cancer types, while targets of REST and SMAD4 were enriched in all cancers except for 282 
clear cell renal cell carcinoma (Fig. 3D). These TFs were thought to induce epithelial-283 
mesenchymal transition and promote invasion and metastasis consistent with their roles in 284 
tumour initiation and maintenance(30–32).  285 
 286 
To independently confirm that the 13-gene signature is a potential pan-cancer marker of 287 
CSCs, we performed Spearman’s correlation analyses to compare 13-gene scores with 288 
expression profiles of other CSC markers where we would expect to see positive correlations. 289 
We examined expression profiles of nine genes implicated in CSC regulation: CD105, CD133, 290 
CD200, CD24, CD29, CD44, CD73, CD90 and NESTIN. Putative neural CSC markers are CD133, 291 
NESTIN, CD105 and CD44(33). We observed significant positive correlations between 13-gene 292 
scores and all four markers in glioma samples (Fig. S4). CD105, CD29, CD44, CD73, CD90 and 293 
NESTIN were positively correlated with 13-gene scores in renal cancers (Fig. S4); an 294 
observation which is consistent with these genes being markers of renal CSCs(34). Seven and 295 
four CSC markers were positively correlated with 13-gene scores in liver and stomach cancers 296 
respectively (Fig. S4). Given the tissue-specific nature of these genes, we would not expect to 297 
see positive correlations in all cases. Nonetheless, our results overall suggest that hyperactive 298 
Notch-Hedgehog signalling is associated with CSC phenotypes, contributing to tumour 299 
aggression and poor survival outcomes.    300 
 301 
 302 
Transcription factors involved in self-renewal processes influence survival outcomes in patients 303 
with hyperactive Notch-Hedgehog signalling  304 
 305 
Previously, we observed that binding targets of TFs associated with stem cell function were 306 
enriched amongst DEGs (Fig. 3D). Polycomb proteins, EZH2 and SUZ12 have been implicated 307 
in CSC formation and maintenance(35,36). REST is a transcriptional repressor involved in 308 
maintaining embryonic and neural stem cell phenotypes(37). Given their roles in CSC 309 
maintenance, we would expect to see elevated expression of these TFs in tumours with 310 
hyperactive Notch-Hedgehog signalling. Indeed, we observed significant positive correlations 311 
between 13-gene scores and EZH2 levels in glioma (rho=0.45; P<0.0001), clear cell renal cell 312 
(rho=0.22; P<0.0001), papillary renal cell (rho=0.33; P<0.0001) and liver (rho=0.26; P<0.0001) 313 
cancers (Fig. 4A). Additionally, in the glioma cohort, positive associations between 13-gene 314 
scores and REST (rho=0.39; P<0.0001) or SUZ12 (rho=0.17; P<0.0001) profiles were observed 315 
(Fig. 4D).  316 
 317 
To determine whether these associations harboured prognostic information, patients were 318 
categorised by their 13-gene scores and expression profiles of individual TFs into four 319 
categories: 1) high 13-gene score and high TF expression, 2) high 13-gene score and low TF 320 
expression, 3) low 13-gene score and high TF expression and 4) low 13-gene score and low TF 321 
expression (Fig. 4A and 4D). Interestingly, combined relationship of the signature and TF 322 
expression profiles allowed further delineation of patients into additional risk groups: glioma 323 
(EZH2: P<0.0001; REST: P<0.0001 and SUZ12: P<0.0001), clear cell renal cell (EZH2: 324 
P<0.0001), papillary renal cell (EZH2: P=0.029) and liver (EZH2: P<0.00057) cancers (Fig. 4B 325 
and 4E).  Patients with high 13-gene scores that concurrently harboured high TF expression 326 
had the poorest survival outcomes: glioma (EZH2: HR=5.141, P<0.0001; REST: HR=3.646, 327 
P<0.0001; SUZ12: HR=3.596, P<0.0001), clear cell renal cell (EZH2: HR=2.854, P<0.0001), 328 
papillary renal cell (EZH2: HR=4.391, P=0.0099) and liver (EZH2: HR=2.685, P=0.0005) cancers 329 
(Fig. 4C and 4F). Taken together, our results suggest that coregulation by Notch-Hedgehog 330 
signalling and CSC TFs could synergistically contribute to more advanced disease states.  331 
 332 
 333 
Tumour hypoxia exacerbates disease phenotypes in Notch-Hedgehog+ CSCs 334 
 335 
Hypoxia is intricately linked to pluripotency as it promotes stem cell maintenance and self-336 
renewal in both embryonic stem cells and CSCs(38), in part, through modulating hypoxia-337 
inducible factor (HIF) function(39). For example, glioma stem cells are typically found in the 338 
vicinity of necrotic regions that are hypoxic(40). Glioma stem cells have increased ability to 339 
stimulate angiogenesis through VEGF upregulation(41) and inhibition of HIFs could reduce 340 
CSC survival, self-renewal and proliferation(40). We reason that hypoxia functions to 341 
maintain CSC niches. To assess the levels of tumour hypoxia, we employed a 52-hypoxia gene 342 
signature(17) for calculating hypoxia scores in each patient by taking the average expression 343 
of hypoxia signature genes(17). Indeed, we observed significant positive correlations 344 
between Notch-Hedgehog+ CSCs and hypoxia scores in glioma (rho=0.33, P<0.0001) and clear 345 
cell renal cell carcinoma (rho=0.16, P=0.00031) (Fig. 5A). By grouping patients based on their 346 
13-gene and hypoxia scores, this joint model allowed the identification of patients with 347 
potentially more hypoxic tumours harbouring Notch-Hedgehog+ CSCs, which influenced 348 
overall survival rates: glioma (P<0.0001) and clear cell renal cell carcinoma (P=0.00013) (Fig. 349 
5B). Indeed, patients with high CSC and hypoxia scores had significantly poorer survival 350 
outcomes: glioma (HR=6.008; P<0.0001) and clear cell renal cell carcinoma (HR=2.389, 351 
P<0.0001) (Fig. 5C). The CSC-hypoxia model is also prognostic in glioma subtypes: 352 
astrocytoma (HR=5.052, P<0.0001), oligoastrocytoma (HR=16.717, P=0.0066) and 353 
glioblastoma (HR=2.686, P=0.022) (Fig. 5B and 5C). Our results suggest that hypoxic zones 354 
within tumours could very well represent CSC niches.  355 
 356 
 357 
Putative Notch-Hedgehog+ CSCs are potentially immune privileged  358 
 359 
Cancer progression is negatively correlated with immunocompetence of the host and 360 
evidence points to the role of CSCs in immunomodulation(3,42). CSCs reside within niches 361 
that are often protected from environmental insults as well as attacks by the immune 362 
system. Hypoxic zones not only serve as CSC niches (Fig. 5)(43), but also attract 363 
immunosuppressive cells such as regulatory T cells (Tregs)(22,44), tumour-associated 364 
macrophages(45) and myeloid-derived suppressor cells(46). Given that positive associations 365 
between Notch-Hedgehog+ CSCs and hypoxia were linked to poor progression in glioma and 366 
clear cell renal cell carcinoma, we hypothesize that tumours characterised by these features 367 
would be immune privileged or hypoimmunogenic.  368 
 369 
To test this hypothesis, we retrieved a list of 31 genes that represent tumour-infiltrating 370 
Tregs. This gene list was identified from the overlap of four Treg signatures(18–21) to yield a 371 
more representative profile of tumour-infiltrating Tregs that is not specific to a single cancer 372 
type. A Treg score for each patient within the glioma and clear cell renal cell carcinoma 373 
cohorts was calculated as the mean expression of the 31 genes. We observed significant 374 
positive correlations between Treg scores and the Notch-Hedgehog 13-gene scores in both 375 
cohorts, supporting the hypothesis that CSCs are potentially hypoimmunogenic: glioma 376 
(rho=0.43; P<0.0001) and clear cell renal cell carcinoma (rho=0.31; P<0.0001) (Fig. 6A). As 377 
performed previously, patients were separated into four groups based on their 13-gene and 378 
Treg scores. When used in combination with the Notch-Hedgehog signature, Treg expression 379 
profiles allowed further separation of patients into additional risk groups that influenced 380 
overall survival: glioma (P<0.0001) and clear cell renal cell carcinoma (P<0.0001) (Fig. 6B). 381 
Intriguingly, patients characterised by high 13-gene and Treg scores had significantly higher 382 
mortality rates compared to those with low 13-gene and Treg scores: glioma (HR=4.921, 383 
P<0.0001) and clear cell renal cell carcinoma (HR=2.968, P<0.0001) (Fig. 6C). This was also 384 
true for other histological subtypes of glioma: astrocytoma (HR=2.721; P=0.0032), 385 
oligoastrocytoma (HR=5.431; P=0.0091) and glioblastoma (HR=3.065; P=0.0068) (Fig. 6C). 386 
Taken together, our results suggest that CSCs found within immunosuppressed environments 387 
are likely to be more aggressive.   388 
Discussion and Conclusion: 389 
 390 
Aberrations in the Notch-Hedgehog signalling axis are frequently implicated in malignant 391 
progression. Hedgehog genes, Shh, PTCH1 and GLI1, were detected in over 50% of liver 392 
cancer tumours and inhibition of Hedgehog signalling by cyclopamine, Smoothened 393 
antagonist or anti-SHH resulted in decreased cell growth and increased apoptosis(47). Notch 394 
signalling is also activated in liver cancer and this leads to formation of liver tumours in 395 
mice(48). Notch blockade using γ-secretase inhibitors reduced cell viability in hepatoma cell 396 
lines(48). In clear cell renal cell carcinoma, inhibition of Notch signalling reduced anchorage-397 
independent growth and mice treated with Notch inhibitors had impaired growth of 398 
transplanted cancer cells(49). Elevated expression of Notch ligands correlated with 399 
aggressiveness and poor survival rates in stomach cancer(50).  400 
 401 
These studies have paved the road for understanding the role of Notch-Hedgehog signalling 402 
in carcinogenesis. However, large-scale comparative studies investigating the similarities and 403 
differences in Notch-Hedgehog signalling across multiple cancer types have remained limited. 404 
We interrogated expression and mutational profiles of 72 genes from Notch and Hedgehog 405 
pathways in 21 diverse cancer types involving 18,484 patients. Our integrated analysis of 406 
genomic, transcriptomic and clinical data revealed molecular distinct tumour subtypes that 407 
were characterised by Notch-Hedgehog hyperactivation. Concentrating on 13 Notch-408 
Hedgehog driver genes that were recurrently amplified and overexpressed, we found that 409 
these genes were associated with clinically relevant molecular features of stemness. The 410 
biological consequences of elevated expression of driver genes were manifold. High-risk 411 
patients showed overexpression of genes associated with other stem cell-related pathways 412 
such as Wnt, JAK-STAT and TGF-β signalling (Fig. 3D. and S3B)(51). Simultaneous inhibition of 413 
Notch and JAK-STAT pathways by combined AG-490 and GSI IX therapy impaired pancreatic 414 
cancer progression(52). GLI2 is regulated by both Hedgehog and TGF-β pathways and others 415 
have surmised that TGF-β may potentiate Hedgehog signalling cascade by increasing GL12 416 
availability, contributing to metastasis(53). Hence, our study reveals molecular targets with 417 
overlapping functions that can be prioritised to improve therapeutic outcomes.  418 
 419 
Furthermore, binding targets of stem cell-related TFs (EZH2, SUZ12 and REST) were enriched 420 
amongst genes upregulated in high-risk patients (Fig. 4). EZH2 synergises with Notch-421 
Hedgehog+ CSCs to worsen survival outcomes in patients with glioma, renal and liver cancers 422 
(Fig. 4). Pharmacological inhibition of EZH2 impaired glioblastoma CSC tumour-initiating 423 
capacity and survival(35). EZH2-mediated transcriptional silencing leads to the maintenance 424 
of undifferentiated states in glioblastoma through STAT3 activation(54). In liver cancer, EZH2 425 
overexpression is associated with vascular invasion, malignant progression(55) and activation 426 
of β-catenin/Wnt signalling(56). Inhibition of EZH2 in renal cancer cell lines led to increased 427 
apoptosis(57). Additionally, enrichments of SUZ12 and REST targets in glioma patients with 428 
hyperactive Notch-Hedgehog signalling were linked to significantly poorer prognosis (Fig. 4D 429 
and 4E). REST is implicated in transcriptional regulation of neuronal stem cells(37), while the 430 
overexpression of SUZ12 is linked to tumour progression(58).   431 
 432 
An exploration of the relationship between Notch-Hedgehog hyperactivation and tumour 433 
microenvironmental qualities revealed associations of CSCs with hypoxia and 434 
immunosuppression.  We observed that CSCs characterised by hyperactive Notch-Hedgehog 435 
signalling exhibited immune privileged features associated with the attenuation effects of 436 
Tregs (Fig. 6). Effectiveness of immunotherapy is biased towards differentiated cells that 437 
make up the tumour bulk due to distinct antigen presentation in CSCs(59). CD133+ glioma 438 
CSCs fail to express NK cell ligands or MHCI, which prevents immune detection(60). 439 
Stimulatory NK cell ligands are also downregulated in breast CSCs, contributing to evasion 440 
from NK cell killing(61). Pan et al. elegantly reviewed recent initiatives focusing on 441 
immunotherapeutic agents against CSC antigens employing dendritic cell vaccines, myeloid-442 
derived suppressor cell-based approaches and the use of immune checkpoint blockades 443 
recognising PD-1 or CTLA4(59). The Notch-Hedgehog signature may be used to stratify 444 
patients prior to immunotherapy.  445 
 446 
Immunoevasion can be exacerbated by tumour hypoxia as the latter not only promotes CSC 447 
survival, but also creates an environment that facilitates further immune suppression(22). It 448 
may be possible that Notch-Hedgehog+ CSCs in glioma and clear cell renal cell carcinomas are 449 
more frequently found within immunosuppressed hypoxic zones (Fig. 5). Indeed, hypoxia 450 
could stimulate self-renewal of CD133+ glioma stem cells and this is abrogated by HIF-1α 451 
knockdown(62). Hypoxia promotes the maintenance of undifferentiated states through the 452 
activation of Notch-responsive genes in neuronal progenitors(39). Hypoxia also activates 453 
cellular reprogramming of non-stem cancer cells into CSCs in glioblastoma by inducing the 454 
expression of Oct4, Nanog and c-Myc(63). Glioma stem cells are pro-angiogenic due to 455 
promiscuous secretions of VEGF that is further induced by hypoxia(41). Bevacizumab, which 456 
targets VEGF, could suppress xenographs derived from glioma stem cells but not those 457 
derived from non-stem glioma cells(41). In renal cancer, we observed that Notch-Hedgehog+ 458 
CSCs are likely to be enriched in hypoxic tumours and the combined effects of hypoxia and 459 
augmented Notch-Hedgehog signalling resulted in further elevation of death risks (Fig. 5). 460 
However, Sjölund et al. observed that Notch signalling is not enhanced by hypoxia in renal 461 
cancer(49). Another study on renal CSCs revealed that hypoxia did not affect the 462 
differentiation potential of CD105+ CSCs(64). Nonetheless, hypoxia was found to induce the 463 
expression of stem cell markers, Oct4, Nanog, c-Myc and Klf4 in renal cancer cell lines, 464 
supporting our observation, and in another ten cancers including cervix, lung, colon, liver and 465 
prostate(65).  466 
 467 
Although prospective validation is warranted, the results presented in this work support a 468 
model where Notch-Hedgehog hyperactivation is linked to stemness and that hypoxia 469 
contributes to the maintenance of undifferentiated phenotypes and the reduction of anti-470 
tumour immunity. The use of immune checkpoint blockade has been increasingly tried in 471 
malignancy(66). Hence, molecular signatures capable of discerning responders from non-472 
responders will be valuable prior to the administration of these expensive drugs. As an 473 
independent prognostic indicator in five cancer types involving 2,278 patients, the Notch-474 
Hedgehog gene signature may serve as a staging point for exploring combinatorial 475 
treatments that simultaneously target CSCs, hypoxia and tumour immunity.  476 
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Figure Legends: 694 
 695 
Figure 1. Pan-cancer drivers of Notch-Hedgehog signalling. (A) Schematic diagram illustrating 696 
the study design and the identification of Notch-Hedgehog driver genes, which represent the 697 
13-gene signature. SCNA and expression profiles of 72 Notch-Hedgehog pathway genes were 698 
interrogated in 21 cancer types involving 18,484 patients. We identified 70 genes as 699 
amplified in at least 20% of samples and 35 genes that were amplified in at least 20% of 700 
samples in at least 7 cancer types. Differential expression analyses between tumour and non-701 
tumour samples revealed that the 13 recurrently amplified genes were also upregulated, 702 
potentially indicating a gain-of-function. These 13 genes were prioritised as a Notch-703 
Hedgehog signature, which was prognostic in five cancer types involving 2,278 patients. 704 
Associations of the signature with tumour microenvironmental features of hypoxia and 705 
immunity were also investigated. Pie slices indicate the number of samples within each 706 
cancer type. (B) Stacked bar graphs represent the proportion of samples in each cancer type 707 
with SCNA of Hedgehog and Notch pathway genes. Width of the bars reflect the number of 708 
samples within each cancer. (C) Somatic gains and differential expression profiles of 35 709 
Notch-Hedgehog genes that were recurrently amplified in at least 7 cancer types (one-third 710 
of all cancers). Cumulative bar charts on the left represent the number of cancers with at 711 
least 20% of samples with somatic amplification. Heatmap on the left represents the extent 712 
of somatic gains for each of the 35 genes separated into Hedgehog and Notch signalling 713 
pathways across 21 cancers. Heatmap intensities depict the fraction of the cohort in which a 714 
given gene is amplified. Columns (cancer types) were ordered using Euclidean distance 715 
metric and hierarchical clustering to reveal cancers that were similar. Heatmap on the right 716 
represents tumour and non-tumour differential expression values (log2) for the 35 genes. 717 
Genes highlighted in red represent the 13 Notch-Hedgehog signature genes. Cancer 718 
abbreviations were listed in Table S2.    719 
 720 
Figure 2. The Notch-Hedgehog 13-gene signature predicts patient survival in five cancers. (A) 721 
Kaplan-Meier estimates for overall survival using the signature. Patients were ranked and 722 
quartile stratified into Q1 (<25%), Q2 (25-50%), Q3 (50-75%) and Q4 (>75%) based on their 723 
13-gene scores. P values were determined using the log-rank test. (B) Separation of tumour 724 
from non-tumour samples using the signature. Ordination plots of MDS analysis of the 725 
signature using Euclidean distances to represent tumour and non-tumour samples in 2-726 
dimensional space. PERMANOVA test confirmed statistically significant differences between 727 
tumour and non-tumour samples. 728 
 729 
Figure 3. The Notch-Hedgehog 13-gene signature is independent of TNM stage and predicts 730 
overall survival in glioma histological subtypes. (A) Kaplan-Meier analyses were performed on 731 
patients stratified according to TNM stages and 13-gene scores. Patients were first separated 732 
into TNM stage and then median-stratified into low- and high-score groups based on their 733 
13-gene scores. P values were determined using the log-rank test. (B) Kaplan-Meier estimates 734 
for overall survival using the signature on glioma subtypes ranging from low-grade 735 
(astrocytoma, oligoastrocytoma) to high-grade gliomas (glioblastoma multiforme). Patients 736 
were first stratified by histological subtypes followed by quartile stratification into Q1 (<25%), 737 
Q2 (25-50%), Q3 (50-75%) and Q4 (>75%) based on their 13-gene scores. P values were 738 
determined using the log-rank test. (C) Predictive performance of the signature. The receiver 739 
operating characteristic (ROC) analysis was used to assess specificity and sensitivity of the 740 
signature in predicting 5-year overall survival. ROC curves generated from the signature were 741 
compared to those generated from TNM staging and a combined model uniting TNM stage 742 
and the signature. AUCs for TNM stage were in accordance with previous publications 743 
employing TCGA datasets(2,22,51). AUC: area under the curve. TNM: tumour, node and 744 
metastasis. (D) Enriched biological pathways and transcription factor binding associated with 745 
DEGs. Differential expression analyses were performed between Q4 and Q1 patients 746 
followed by mapping of DEGs against KEGG, Gene Ontology, ChEA and ENCODE databases.  747 
 748 
Figure 4. Prognostic significance of a combined model of the Notch-Hedgehog signature and 749 
transcription factors (EZH2, SUZ12 and REST) involved in pluripotency maintenance. (A) Scatter 750 
plots demonstrate significant positive correlations between 13-gene scores and EZH2 751 
expression profiles in four cancers. Patients were stratified into four categories based on 752 
median 13-gene scores and EZH2 expression. Density plots depict the distribution of 13-gene 753 
scores and EZH2 expression at the y- and x-axes respectively. (B) Kaplan-Meier analyses were 754 
performed on the four patient categories to ascertain the combined relationship of the 755 
signature and EZH2 expression on overall survival. (C) Table inset depicts univariate Cox 756 
proportional hazards analyses of the relationship between EZH2 and the signature in four 757 
cancer types. (D) Scatter plots demonstrate significant positive correlations between 13-gene 758 
scores and REST or SUZ12 expression levels in glioma. Patients were stratified into four 759 
categories based on median 13-gene score and REST or SUZ12 expression. Density plots 760 
depict the distribution of 13-gene scores and REST or SUZ12 expression at the y- and x-axes 761 
respectively. (E) Kaplan-Meier analyses were performed on the four patient categories to 762 
ascertain the combined relationship between the signature and REST or SUZ12 expression on 763 
overall survival in glioma. (F) Table inset depicts univariate Cox proportional hazards analyses 764 
of the relationship between REST or SUZ12 and the signature in glioma. CI: confidence 765 
interval. Significant P values are highlighted in bold.  766 
 767 
 768 
Figure 5. Positive associations between Notch-Hedgehog+ CSCs and tumour hypoxia in glioma 769 
and clear cell renal cell carcinoma. (A) Scatter plots demonstrate significant positive 770 
correlations between 13-gene and hypoxia scores. Patients were stratified into four 771 
categories based on median 13-gene and hypoxia scores. Density plots depict the distribution 772 
of 13-gene and hypoxia scores at the y- and x-axes respectively. (B) Kaplan-Meier analyses 773 
were performed on the four patient categories to ascertain the combined relationship of the 774 
signature and tumour hypoxia on overall survival. Contribution of hypoxia on Notch-775 
Hedgehog+ CSCs were also determined in histological subtypes of glioma (astrocytoma, 776 
oligoastrocytoma and glioblastoma multiforme). (C) Table inset demonstrates univariate Cox 777 
proportional hazards analyses of the relationship between tumour hypoxia and the signature 778 
in glioma and clear cell renal cell carcinoma. CI: confidence interval. Significant P values are 779 
highlighted in bold. 780 
 781 
 782 
Figure 6. Positive associations between Notch-Hedgehog+ CSCs and immunosuppression in 783 
glioma and clear cell renal cell carcinoma. (A) Scatter plots demonstrate significant positive 784 
correlations between 13-gene and Treg scores. Patients were stratified into four categories 785 
based on median 13-gene and Treg scores. Density plots depict the distribution of 13-gene 786 
and Treg scores at the y- and x-axes respectively. (B) Kaplan-Meier analyses were performed 787 
on the four patient categories to ascertain the combined relationship of the signature and 788 
Treg-mediated immunosuppression on overall survival. Contribution of Tregs on Notch-789 
Hedgehog+ CSCs were also determined in histological subtypes of glioma (astrocytoma, 790 
oligoastrocytoma and glioblastoma multiforme). (C) Table inset demonstrates univariate Cox 791 
proportional hazards analyses of the relationship between Tregs and the signature in glioma 792 
and clear cell renal cell carcinoma. CI: confidence interval. Significant P values are highlighted 793 
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34 Hedgehog & 38 Notch pathway genes
21 cancer types (n=18,484)
Somatic copy number alteration (SCNA)
Tumour vs. non-tumour differential expression
70 genes amplified in > 20% samples per cancer type
35 genes amplified in > 20% samples in at least 7 cancers
13 genes upregulated > 1.5 fold (Driver genes)
13 driver gene signature
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57 39 18 6 3 2
57 40 12 5 0 0
65 48 26 13 5 4
66 45 20 5 2 1
9 6 3 2 1 1


















Astrocytoma Oligoastrocytoma Glioblastoma multiforme
Renal clear cell: TNM staging Papillary renal cell: TNM staging












































































Complement and coagulation cascades
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182 139 96 65 37 27
185 130 58 27 15 9
111 82 48 36 19 15
112 83 49 32 20 14
Number at risk
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146 127 106 88 74 57
148 115 92 70 46 24
115 97 77 65 50 35
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Years
75 67 46 29 20 14
76 61 32 21 13 7
52 39 27 19 16 15
53 49 33 18 16 10
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Years
95 76 35 24 20 16
99 59 32 20 12 6
59 52 34 21 15 10
60 47 30 19 12 7
Number at risk
Glioma: EZH2 Renal clear cell: EZH2 Papillary renal cell: EZH2 Liver: EZH2
Glioma: EZH2 Renal clear cell: EZH2 Papillary renal cell: EZH2
Liver: EZH2
High signature score & high EZH2 expression High signature score & low EZH2 expression
Low signature score & low EZH2 expressionLow signature score & high EZH2 expression
High signature score & high EZH2 expression High signature score & low EZH2 expression























































188 143 96 63 37 28
190 132 71 45 25 17
106 80 35 18 9 7



















0 1 2 3 4 5
Years
160 117 79 52 31 22
161 112 57 30 14 7
135 100 49 33 20 17
134 105 66 45 26 19
Number at risk
Hazard Ratio (95% CI) P -value
Glioma
High signature score & high REST  vs. low signature score & low REST 3.646 (2.461 - 5.402) 1.12E-10
High signature score & low REST  vs. low signature score & low REST 1.811 (1.097 - 2.990) 0.02
Low signature score & high REST  vs. low signature score & low REST 1.626 (0.994 - 2.658) 0.053
Glioma
High signature score & high SUZ12  vs. low signature score & low SUZ12 3.596 (2.332 - 5.545) 7.03E-09
High signature score & low SUZ12  vs. low signature score & low SUZ12 1.956 (1.227 - 3.118) 0.0048
Low signature score & high SUZ12  vs. low signature score & low SUZ12 1.210 (0.737 - 1.987) 0.45
High signature score & high REST/SUZ12 expression
High signature score & low  REST/SUZ12 expression
Low signature score & low  REST/SUZ12 expression











High signature score & high REST/SUZ12 expression
High signature score & low REST/SUZ12 expression
Low signature score & low REST/SUZ12 expression
Low signature score & high REST/SUZ12 expression
Glioma: REST Glioma: SUZ12
D E
F
Hazard Ratio (95% CI) P -value
Glioma
High signature score & high EZH2  vs. low signature score & low EZH2 5.141 (3.374 - 7.831) 2.48E-14
High signature score & low EZH2  vs. low signature score & low EZH2 1.475 (0.863 - 2.521) 0.15
Low signature score & high EZH2  vs. low signature score & low EZH2 1.936 (1.179 - 3.180) 0.0091
Renal clear cell
High signature score & high EZH2  vs. low signature score & low EZH2 2.854 (1.884 - 4.353) 8.46E-07
High signature score & low EZH2  vs. low signature score & low EZH2 1.360 (0.835 - 2.215) 0.22
Low signature score & high EZH2  vs. low signature score & low EZH2 1.759 (1.116 - 2.774) 0.015
Papillary renal cell
High signature score & high EZH2  vs. low signature score & low EZH2 4.391 (1.427 - 13.513) 9.90E-03
High signature score & low EZH2  vs. low signature score & low EZH2 1.856 (0.498 - 6.924) 0.35
Low signature score & high EZH2  vs. low signature score & low EZH2 2.008 (0.566 - 7.119) 0.28
Liver
High signature score & high EZH2  vs. low signature score & low EZH2 2.685 (1.540 - 4.683) 5.00E-04
High signature score & low EZH2  vs. low signature score & low EZH2 1.089 (0.548 - 2.163) 0.81
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35 29 17 14 4 2
35 26 13 9 3 2
30 26 11 6 2 1
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Years
16 8 3 1 0 0
17 5 0 0 0 0
21 13 2 0 0 0
21 12 3 0 0 0
Number at risk
Hazard Ratio (95% CI) P -value
Glioma
High signature & high hypoxia scores vs. low signature & low hypoxia scores 6.008 (3.939 - 9.161) 2.00E-16
High signature & low hypoxia scores vs. low signature & low hypoxia scores 0.996 (0.545 - 1.821) 0.98
Low signature & high hypoxia scores vs. low signature & low hypoxia scores 2.048 (1.245 - 3.367) 0.0047
Astrocytoma
High signature & high hypoxia scores vs. low signature & low hypoxia scores 5.052 (2.292 - 11.134) 5.89E-05
High signature & low hypoxia scores vs. low signature & low hypoxia scores 1.578 (0.589 - 4.223) 0.36
Low signature & high hypoxia scores vs. low signature & low hypoxia scores 3.827 (1.571 - 9.322) 0.0031
Oligoastrocytoma
High signature & high hypoxia scores vs. low signature & low hypoxia scores 16.717 (2.189 - 127.670) 6.60E-03
High signature & low hypoxia scores vs. low signature & low hypoxia scores 4.310 (0.447 - 41.540) 0.21
Low signature & high hypoxia scores vs. low signature & low hypoxia scores 5.383 (0.646 - 44.830) 0.12
Glioblastoma
High signature & high hypoxia scores vs. low signature & low hypoxia scores 2.686 (1.151 - 6.270) 2.20E-02
High signature & low hypoxia scores vs. low signature & low hypoxia scores 1.635 (0.771 - 3.473) 0.2
Low signature & high hypoxia scores vs. low signature & low hypoxia scores 0.799 (0.363 - 1.759) 0.58
Renal clear cell
High signature & high hypoxia scores vs. low signature & low hypoxia scores 2.389 (1.575 - 3.625) 4.23E-05
High signature & low hypoxia scores vs. low signature & low hypoxia scores 1.330 (0.829 - 2.135) 0.24
Low signature & high hypoxia scores vs. low signature & low hypoxia scores 1.350 (0.857 - 2.126) 0.19
High signature & high hypoxia scores High signature & low hypoxia scores
Low signature & low hypoxia scoresLow signature & high hypoxia scores
Glioma
Renal clear cell
Glioma Renal clear cell
Astrocytoma Oligoastrocytoma Glioblastoma
High signature & high hypoxia scores
High signature & low hypoxia scores
Low signature & low hypoxia scores
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196 155 103 70 42 29
198 129 63 36 20 13
98 83 43 27 14 11
98 67 42 27 15 12
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147 125 107 92 75 55
149 121 93 72 51 32
114 91 76 63 45 27
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32 28 16 11 6 5
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38 31 17 14 5 3
38 28 13 8 4 2
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15 9 3 0 0 0
22 11 1 0 0 0
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High signature & high Treg scores High signature & low Treg scores
Low signature & low Treg scoresLow signature & high Treg scores
Hazard Ratio (95% CI) P -value
Glioma
High signature & high Treg scores vs. low signature & low Treg scores 4.921 (3.277 - 7.391) 1.60E-14
High signature & low Treg scores vs. low signature & low Treg scores 1.671 (0.989 - 2.822) 0.055
Low signature & high Treg scores vs. low signature & low Treg scores 2.377 (1.459 - 3.872) 0.000503
Astrocytoma
High signature & high Treg scores vs. low signature & low Treg scores 2.721 (1.398 - 5.298) 3.20E-03
High signature & low Treg scores vs. low signature & low Treg scores 1.288 (0.561 - 2.960) 0.55
Low signature & high Treg scores vs. low signature & low Treg scores 1.457 (0.597 - 3.554) 0.41
Oligoastrocytoma
High signature & high Treg scores vs. low signature & low Treg scores 5.431 (1.522 - 19.374) 9.10E-03
High signature & low Treg scores vs. low signature & low Treg scores 2.470 (0.576 - 10.603) 0.22
Low signature & high Treg scores vs. low signature & low Treg scores 1.032 (0.222 - 4.804) 0.97
Glioblastoma
High signature & high Treg scores vs. low signature & low Treg scores 3.065 (1.362 - 6.900) 0.0068
High signature & low Treg scores vs. low signature & low Treg scores 1.955 (0.824 - 4.639) 0.13
Low signature & high Treg scores vs. low signature & low Treg scores 1.274 (0.570 - 2.846) 0.55
Renal clear cell
High signature & high Treg scores vs. low signature & low Treg scores 2.968 (1.922 - 4.582) 9.20E-07
High signature & low Treg scores vs. low signature & low Treg scores 1.649 (0.997 - 2.728) 0.051
Low signature & high Treg scores vs. low signature & low Treg scores 2.132 (1.342 - 3.385) 0.0013
Glioma Renal clear cell
Astrocytoma Oligoastrocytoma Glioblastoma
High signature & high Treg scores
High signature & low Treg scores
Low signature & low Treg scores
Low signature & high Treg scores
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